An Open-Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy

Trial Profile

An Open-Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2017

At a glance

  • Drugs DEX M74 (Primary)
  • Indications Nonaka distal myopathy
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 02 Mar 2017 Planned End Date changed from 4 Aug 2017 to 30 Aug 2018.
    • 02 Mar 2017 Planned primary completion date changed from 4 Aug 2017 to 30 Dec 2017.
    • 16 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top